EE81 The Budget Impact of Cangrelor for the Treatment of Patients Undergoing Percutaneous Coronary Intervention When Oral P2Y12 Inhibitors Are Not Feasible or Desirable in the UK
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.333
https://www.valueinhealthjournal.com/article/S1098-3015(22)02537-2/fulltext
Section Title :
Section Order :
12139
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02537-2&doi=10.1016/j.jval.2022.09.333